Kenvue v první polovině roku zvýšila upravenou provozní marži o 180 bazických bodů na 23,1 % a upravený zisk vzrostl o 18,9 %. Růst tržeb ale zůstal slabý, když organické prodeje stouply jen o 1,2 %.
Key Takeaways Kenvue's first-half adjusted operating margin rose 180 basis points to 23.1% as earnings climbed 18.9%.Cost cuts aided profitability, while second-quarter inflation and tariffs pressured Kenvue's margins.Kenvue's Skin Health and Beauty sales grew 4.4%, but Self Care sales and volumes remained under pressure. Kenvue Inc. (KVUE - Free Report) is showing better earnings leverage than its sales growth alone would suggest. In the first half of 2026, adjusted operating margin rose 180 basis points to 23.1% and adjusted earnings increased 18.9% to 63 cents per share.
The improvement is encouraging, but revenue momentum remains modest. First-half organic sales grew only 1.2%, with volume up 0.2%, while the company continues to manage tariff, inflation, debt and transaction-related risks.
Cost discipline is doing much of the work. Supply-chain optimization, restructuring benefits and lower administrative expenses supported first-half profitability. Kenvue expects its 2026 Restructuring Initiative to generate about $200 million of annualized pre-tax gross savings upon completion, although the program is also expected to require about $250 million of pre-tax charges in 2026.Kenvue Inc. Price, Consensus and EPS Surprise
The second quarter showed why investors should not assume margin expansion will be linear. Organic sales improved to 1.6%, but adjusted gross margin declined 70 basis points to 60.2% as inflation, tariffs and transactional foreign exchange outweighed pricing and productivity gains. Adjusted operating margin also narrowed 60 basis points to 22.1% as Kenvue increased brand investment.
The sales mix remains uneven. Skin Health and Beauty was the clearest growth engine in the first half, with organic sales up 4.4% and segment adjusted operating income rising 46.9% to $354 million. Self Care moved back to 0.6% organic growth in the second quarter, yet first-half organic sales still declined 0.9% and volumes fell 2.3%. That leaves Kenvue exposed to seasonal illness patterns and slower category demand.
Cash generation offers some support. Operating cash flow increased 12.2% to $1.2 billion in the first six months of 2026 and free cash flow rose to about $1 billion. Still, total debt remained $8.5 billion at the end of the second quarter. Kenvue is also withholding forward financial guidance while its pending combination with Kimberly-Clark moves toward an expected fourth-quarter 2026 closing, subject to remaining approvals and conditions.
Image Source: Zacks Investment Research
Valuation is not demanding relative to several benchmarks. KVUE trades at 15.6X forward 12-month earnings, below the Zacks sub-industry's 18.7X multiple and its own five-year median of 16.8X. On fiscal-year-one earnings, KVUE's 16.4X multiple is also below Church & Dwight Co., Inc. (CHD - Free Report) at 26.1X. Church & Dwight provides a useful consumer-staples benchmark for how investors are valuing a peer with a higher earnings multiple.
The Procter & Gamble Company (PG - Free Report) offers another large-cap consumer-products comparison. PG trades at 21.0X fiscal-year-one earnings, again above KVUE. These peer gaps support the argument that Kenvue's slower growth and execution risks are already reflected to some degree in its valuation, but a discount alone does not establish a near-term buying signal.
The bottom line is that Kenvue's improving first-half profitability, stronger cash flow and healthier Skin Health and Beauty trends are offset by modest organic growth, weak Self Care volumes, quarterly margin pressure and $8.5 billion of debt. The risk-reward profile looks balanced rather than decisively favorable.
KVUE currently carries a Zacks Rank #3 (Hold), along with a Value Score of C, Growth Score of C, Momentum Score of D and VGM Score of D.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
A Zacks Rank #3 can support holding an existing position, while the weaker Momentum and VGM scores reduce the case for an aggressive new entry. Investors may want firmer evidence of sustained volume growth and more consistent margin expansion before treating the current valuation discount as a clear buying opportunity.
Australský regulátor schválil převzetí společnosti Kenvue firmou Kimberly-Clark za 40 miliard USD, ale jen pod podmínkou prodeje značek Carefree a Stayfree v Austrálii. Cílem je zachovat konkurenci na trhu menstruačních potřeb.
Australia's competition regulator on Wednesday approved Kimberly-Clark's (KMB.O) proposed $40 billion takeover of Kenvue (KVUE.N), on condition the company divests Kenvue's Carefree and Stayfree period care brands in the country to address competition concerns.
Here are the details:
The Australian Competition and Consumer Commission (ACCC) said the period care brands should be divested to an approved purchaser.
The regulator said without the divestment, the deal could lessen competition in period care products supply, with both companies being two of the three major suppliers of period care products in Australia.
The deal, announced in November, would allow Kimberly-Clark to bring in Kenvue's famous global brands such as Listerine mouthwash and Neutrogena, but would expose the company to lawsuits Kenvue faces over Tylenol.
Kimberly-Clark has also sought approval from EU regulators for the takeover, documents on the EU Commission's website showed last week.
"The divestiture will preserve an independent competitor in the supply of period care products in Australia and maintain the competition that would otherwise be lost through the acquisition," ACCC Commissioner Philip Williams said.
Kenvue ve 2. čtvrtletí zvýšila tržby o 3 % na 3,96 miliardy USD a upravený EPS na 31 centů. Tahounem byl segment Skin Health and Beauty, jehož prodeje vzrostly o 5,1 %.
Key Takeaways Kenvue's Q2 sales rose 3%, while adjusted EPS increased to 31 cents from 29 cents. Kenvue's Skin Health and Beauty sales rose 5.1%, led by Hair Care and Face Care.Kenvue is pursuing productivity, digital and brand investments ahead of its planned Kimberly-Clark deal. Kenvue Inc. (KVUE - Free Report) , the world's leading pure-play consumer health company, delivered year-over-year improvement in second-quarter 2026, although earnings and sales slightly missed the respective Zacks Consensus Estimate. Net sales rose 3% year over year to $3.96 billion, while organic sales increased 1.6%. Kenvue's second-quarter 2026 top-line performance improved meaningfully from the year-ago period, marking a sharp reversal from the reported sales decline of 4.0% and organic sales drop of 4.2%.
Profitability strengthened year over year. On the bottom line, Kenvue adjusted earnings of 31 cents per share increased 6.9% year over year in second-quarter 2025. The increase shows that the company benefits from tighter cost control and operating improvements. The quarter extended the improvement seen at the start of 2026, with organic growth supported by a combination of higher prices and improved volume trends. Kenvue delivered its third consecutive quarter of net and organic sales growth, with broad-based gains across all segments and regions. (Read more: KVUE Q2 Earnings Miss Estimates as Margins Narrows, Sales Rise)
We note that Kenvue’s shares have declined 3.2% since it released its second-quarter results on Aug. 6, 2026, before market open. The decline may be attributable to the company’s soft quarterly performance, as both adjusted earnings and revenues fell short of the Zacks Consensus Estimate. However, shares of the Zacks Rank #3 (Hold) company have jumped 10.1% in the past three months compared with the industry's growth of 6.1%.
Image Source: Zacks Investment Research
KVUE's Q2 Key Financial Metrics DiscussionKenvue's three operating segments remain central to its trajectory: Self Care, Skin Health and Beauty, and Essential Health. Skin Health and Beauty remained the key growth driver in the reported quarter, supported by broad-based gains across regions, with Hair Care and Face Care leading the performance. Strong e-commerce momentum, disciplined commercial execution and demand for products such as OGX Pro Growth + Peptide and Neutrogena Ultra Sheer Sun further supported results.
Skin Health and Beauty sales increased 5.1% year over year to $1,113 million, exceeding the Zacks Consensus Estimate of $1,091 million. Organic sales increased 3.7% on higher pricing and volumes, while foreign exchange also contributed to the upside.
Self Care sales increased 2.2% to $1,589 million; however, the metric missed the Zacks Consensus Estimate of $1,617 million. Organic sales rose 0.6% year over year on higher pricing and positive foreign currency, somewhat offset by weak volumes.
Essential Health sales increased 2.3% to $1,253 million, missing the Zacks Consensus Estimate of $1,274 million. However, organic sales rose 1.1%, as volume growth more than offset unfavorable pricing mix. Foreign currency aided results.
What’s More For KVUE?Beyond the quarterly numbers, the pending Kimberly-Clark transaction remains a major strategic factor. Kenvue is simultaneously pursuing restructuring and operational-efficiency initiatives while preparing for the combination, which management expects to close in the fourth quarter of 2026, subject to foreign regulatory approvals and other customary conditions.
Kenvue is focused on strengthening its leading consumer health brands through innovation, targeted marketing and improved execution. The company is prioritizing its largest brands and markets while investing in new products that address evolving consumer needs. KVUE is also expanding its e-commerce and digital capabilities to improve consumer engagement. It is leveraging its global footprint to expand across international markets and drive growth in core categories.
The company continued to enhance operational efficiency while increasing strategic investments to support sustainable growth. Management noted that first-half 2026 results met or surpassed expectations across core metrics, underscoring the resilience of its brands and the progress of strategic execution. Kenvue remains focused on transformation, improving business performance and driving long-term growth.
Stocks to Consider in the Consumer Staples SpaceUnited Natural Foods (UNFI - Free Report) , which is the leading distributor of natural, organic and specialty food and non-food products, currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for United Natural Foods’ current financial-year sales indicates a drop of 2.1% from the prior-year level. UNFI delivered a trailing four-quarter earnings surprise of 29.9%, on average.
Medifast, Inc. (MED - Free Report) , which is a leading manufacturer and distributor of clinically-proven healthy living products and programs, currently carries a Zacks Rank #2 (Buy). MED missed the average earnings surprise by a sharp margin in the trailing four quarters.
The Zacks Consensus Estimate for Medifast’s current financial-year sales indicates a decline of 25.9% from the year-ago number.
Freshpet, Inc. (FRPT - Free Report) , which manufactures and markets natural fresh foods, refrigerated meals, and treats for dogs and cats, currently carries a Zacks Rank of 2.
The Zacks Consensus Estimate for Freshpet’s current financial-year sales indicates growth of 10.7% from the prior-year level. FRPT delivered a trailing four-quarter earnings surprise of 21.9%, on average.
Kenvue za 2. čtvrtletí vykázala zisk 0,31 USD na akcii, což je pod odhadem 0,32 USD. Tržby ve výši 3,96 miliardy USD také mírně zaostaly za očekáváním.
Kenvue (KVUE - Free Report) came out with quarterly earnings of $0.31 per share, missing the Zacks Consensus Estimate of $0.32 per share. This compares to earnings of $0.29 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -3.13%. A quarter ago, it was expected that this consumer health company would post earnings of $0.27 per share when it actually produced earnings of $0.32, delivering a surprise of +18.52%.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.
Kenvue, which belongs to the Zacks Consumer Products - Staples industry, posted revenues of $3.96 billion for the quarter ended June 2026, missing the Zacks Consensus Estimate by 0.86%. This compares to year-ago revenues of $3.84 billion. The company has topped consensus revenue estimates two times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Kenvue shares have added about 14% since the beginning of the year versus the S&P 500's gain of 12.8%.
What's Next for Kenvue?While Kenvue has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Kenvue was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.30 on $3.9 billion in revenues for the coming quarter and $1.16 on $15.6 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Consumer Products - Staples is currently in the bottom 18% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Ollie's Bargain Outlet (OLLI - Free Report) , another stock in the same industry, has yet to report results for the quarter ended July 2026.
This retailer is expected to post quarterly earnings of $1.15 per share in its upcoming report, which represents a year-over-year change of +16.2%. The consensus EPS estimate for the quarter has been revised 2.4% lower over the last 30 days to the current level.
Ollie's Bargain Outlet's revenues are expected to be $761.06 million, up 12% from the year-ago quarter.
Kenvue čeká za 2. čtvrtletí růst tržeb na 4 miliardy USD a zisku na 32 centů na akcii. Tahounem má být Skin Health and Beauty, zatímco rizikem zůstávají cla, inflace a slabá sezónnost.
Key Takeaways KVUE is expected to post Q2 revenue and earnings growth, supported by iconic consumer health brands.Skin Health and Beauty is expected to grow 3%, while Tylenol, Zyrtec and Nicorette trends support demand.Tariffs, inflation, FX and weak seasonal incidence remain key risks to Kenvue's performance. Kenvue Inc. (KVUE - Free Report) is slated to report second-quarter 2026 results on Aug. 6, before market open. The company is likely to report top and bottom-line increase when it posts the quarterly results.
For revenues, the consensus mark is pegged at $4 billion, implying a rise of 3.9% from the year-ago quarter. The Zacks Consensus Estimate for the company’s earnings is pegged at 32 cents per share, which reflects an increase of 10.3% from the year-ago quarter’s figure. The consensus mark has been stable in the past 30 days.
In the last reported quarter, the company delivered an earnings surprise of 18.5%. Its earnings beat the Zacks Consensus Estimate by 12.1%, on average, in the trailing four quarters.
Key Factors to Influence KVUE’s Q2 ResultsKenvue’s quarterly performance is likely to have benefited from its iconic consumer health brands and strength in the Skin Health and Beauty division. The company is focused on strengthening its consumer health brands through product innovation, increased marketing investments and deeper consumer engagement. The Zacks Consensus Estimate for the Skin Health and Beauty segment is currently pegged at $1.1 billion, indicating a rise of 3% year over year.
KVUE’s diversified portfolio reduces dependence on any single product or category. The Tylenol and Zyrtec consumption trends have been improving while Nicorette is gaining share across major international markets, and brand innovation supported broader consumer engagement. Continued investment in these franchises is likely to have boosted sustainable demand and market-share growth in the quarter under review.
The company is prioritizing science-backed innovation and expanding products in categories to drive organic growth. Kenvue is simplifying its operating model, improving supply-chain efficiency and implementing productivity initiatives to reduce costs and support margins. The company is also working to improve execution across markets, optimize its portfolio and enhance digital and e-commerce capabilities. Such factors are likely to have aided the company’s performance during the quarter under review.
On the flip side, the company has been witnessing weakness in its Self Care business for a while. The business remains exposed to unpredictable cold, flu and allergy seasons, which can create volatility in demand. Weak seasonal incidence across major markets has been hurting results, highlighting the segment’s dependence on external health patterns. Also, headwinds like tariffs, inflation, foreign exchange movements and supply-chain volatility remain deterrents.
What the Zacks Model Unveils for KenvueOur proven model does not conclusively predict an earnings beat for Kenvue this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that’s not the case here. You can uncover the best stocks before they’re reported with our Earnings ESP Filter.
Kenvue currently has an Earnings ESP of 0.00% and a Zacks Rank of 3.
Valuation Picture & Price PerformanceKenvue has a forward 12-month price-to-earnings ratio of 16.11X, lower than the Consumer Products - Staples industry’s average of 18.75X. The stock is trading above its median of 15.72X.
The recent market movements show that KVUE’s shares have gained 10.8% in the past three months compared with the industry's 4.2% growth.
Stocks With the Favorable CombinationHere are some companies, which according to our model, have the right combination of elements to beat on earnings this reporting cycle.
Archer Daniels Midland Company (ADM - Free Report) currently has an Earnings ESP of +11.52% and a Zacks Rank of 2. The consensus estimate for ADM’s quarterly revenues is pinned at $22.4 billion, which calls for 5.7% growth from the figure reported in the prior-year quarter. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for Archer Daniels’ upcoming quarter’s EPS is pegged at $1.27, which implies a 36.6% rise year over year. ADM delivered a trailing four-quarter earnings surprise of 5.4%, on average.
Coty (COTY - Free Report) has an Earnings ESP of +0.03% and a Zacks Rank of 3 at present. The company is expected to register a bottom and top-line decline when it reports fourth-quarter fiscal 2026 numbers. The Zacks Consensus Estimate for COTY’s quarterly bottom line has remained unchanged in the past 30 days at a loss of a cent per share. The consensus mark for earnings indicates an improvement of 80% from the figure reported in the year-ago quarter.
The consensus estimate for quarterly revenues is pegged at $1.2 billion, which indicates a drop of 4.8% from the figure reported in the year-ago quarter. COTY has delivered a negative earnings surprise of 214.1%, on average, in the trailing four quarters.
Monster Beverage Corporation (MNST - Free Report) currently has an Earnings ESP of +2.61% and a Zacks Rank of 3. The company is likely to register bottom and top-line growth when it reports second-quarter 2026 numbers.
The Zacks Consensus Estimate for Monster Beverage’s quarterly revenues is pegged at $2.4 billion, indicating an increase of 14.5% from the figure reported in the prior-year quarter. The consensus estimate for MNST’s quarterly earnings of 59 cents per share implies a rise of 13.5% from the year-ago quarter’s level. MNST has a trailing four-quarter earnings surprise of 9.6%, on average.
Kenvue v 1. čtvrtletí 2026 zvýšila upravenou provozní marži na 24 % díky úsporám a lepší efektivitě. Tržby segmentu Skin Health and Beauty vzrostly o 8,4 %.
Key Takeaways Kenvue's diverse portfolio spans self-care, skin health and essential health categories.Kenvue's adjusted operating margin improved to 24% in Q1'26 on efficiency gains.Kimberly-Clark transaction could expand scale, distribution reach and cost opportunities. Kenvue Inc. (KVUE - Free Report) remains a closely watched consumer health name as investors weigh trusted brands, improving margins and a major pending transaction.
The company’s mix of self-care, beauty and everyday health products gives it a broad demand base, but uneven organic growth and execution risks keep the outlook balanced.
Kenvue Builds a Diverse Health PortfolioKenvue operates through Self Care, Skin Health and Beauty, and Essential Health. Its brand lineup includes Tylenol, Zyrtec, Neutrogena, Aveeno, Listerine, Nicorette, Johnson’s and BAND-AID Brand, giving the company exposure to pain care, allergy, smoking cessation, oral care, baby care, wound care, skin care and beauty categories.
That range reduces dependence on one product line and supports repeat-purchase behavior across everyday health needs. Global reach through retailers, pharmacies and digital channels further helps Kenvue serve recurring consumer demand across developed and international markets.
Kenvue Improves Margins Through EfficiencyProfitability has become a central part of the Kenvue story. In the first quarter of 2026, adjusted gross margin expanded 80 basis points to 60.8%, while adjusted operating margin improved 420 basis points to 24%.
The gains reflected supply-chain productivity, favorable value realization and cost optimization actions, including Our Vue Forward and the 2026 Restructuring Initiative. Lower selling, general and administrative expenses also helped offset inflation, tariffs and lower volumes, showing that disciplined spending can support earnings even when sales growth is modest.
Image Source: Zacks Investment Research
Skin Health Drives Kenvue Recovery EffortsSkin Health and Beauty delivered the strongest segment growth in the first quarter. Net sales increased 8.4%, while organic sales rose 5%, supported by 4.2% volume growth and 0.8% favorable value realization.
The segment benefited from innovation, sharper brand activation and targeted e-commerce initiatives. Neutrogena’s entry into sun care in select EMEA markets and the launch of OGX Pro Growth in North America and EMEA supported demand. Adjusted operating income rose to $168 million from $92 million, making the segment an important contributor to the company’s recovery profile.
Kimberly-Clark Deal Creates Strategic PotentialKenvue’s pending cash-and-stock combination with Kimberly-Clark Corporation (KMB - Free Report) adds another strategic dimension. Kenvue shareholders are expected to receive 0.14625 Kimberly-Clark shares plus $3.50 in cash for each Kenvue share, subject to closing conditions.
Shareholders of both companies have approved the required proposals, and the U.S. antitrust waiting period has expired. Foreign regulatory approvals remain outstanding, with closing expected in the second half of 2026. If completed, the transaction could combine Kenvue’s consumer health brands with Kimberly-Clark’s global personal-care platform, creating broader scale, distribution reach and cost opportunities.
The transaction also places Kenvue in a wider consumer staples context. The Procter & Gamble Company (PG - Free Report) , with major beauty, health care and household product categories, remains a useful comparison for investors watching branded consumer product scale and global distribution.
Kenvue’s Market Position Faces Mixed SignalsKenvue’s long-term setup combines durable brands, better profitability and a potential deal catalyst. Still, the stock’s profile is not without offsets, including modest organic growth, Self Care volume pressure, restructuring costs, debt, litigation exposure and limited earnings visibility while the Kimberly-Clark transaction remains pending.
The stock currently carries a Zacks Rank #3 (Hold), which fits a balanced near-term view rather than a clear bullish or bearish signal. Its Value Score of C, Growth Score of C and VGM Score of C suggest average characteristics across valuation, growth and combined style measures, while its Momentum Score of D points to weaker share-price and estimate-revision support.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
For investors, the scores reinforce the need to weigh operating improvements against unresolved risks. Kenvue has credible drivers in brands, efficiency and Skin Health momentum, but broader stock strength may require clearer organic growth, transaction resolution and sustained execution.
Kenvue v 1. čtvrtletí zvýšila upravený EPS o 33 % na 32 centů a provozní marži rozšířila o 420 bazických bodů na 24 %. Volný peněžní tok vzrostl na zhruba 350 milionů USD.
Key Takeaways Kenvue's Q1 adjusted EPS rose 33% as operating margin expanded 420 basis points to 24%.KVUE trades below its sub-industry, sector and S&P 500 forward earnings multiples.Kenvue's free cash flow rose to about $350 million, supporting dividends, debt and brand investment. Kenvue Inc. (KVUE - Free Report) gives investors a consumer health story that is neither simple value nor clear growth. The stock’s appeal rests on better margins, stronger earnings and a portfolio of familiar brands.
The offset is visibility. Organic growth remains modest, debt is elevated and the pending Kimberly-Clark transaction limits the company’s ability to frame its 2026 outlook.
Kenvue Shows Earnings Strength Despite Slow GrowthKenvue reported first-quarter 2026 adjusted earnings of 32 cents per share, up 33% from the prior-year period. Reported sales increased 4.5% to $3.91 billion, helped by a 3.8-percentage-point foreign-currency benefit.
The earnings gain came despite only 0.7% organic sales growth and a 0.3% volume decline. Adjusted gross margin expanded 80 basis points to 60.8%, while adjusted operating margin rose 420 basis points to 24%, reflecting supply-chain productivity, favorable value realization, restructuring benefits and tighter spending.
Kenvue Valuation Offers A Balanced ViewKVUE trades at 16.49X forward 12-month earnings. That is below the 18.41X multiple for its Zacks sub-industry, the 17.28X level for the Zacks sector and the 20.11X multiple for the S&P 500 index.
Image Source: Zacks Investment Research
The $21 price target reflects 17.53X forward 12-month earnings, pointing to a measured view rather than a deeply discounted setup. Haleon plc (HLN - Free Report) gives investors another consumer health reference point, while The Procter & Gamble Company (PG - Free Report) offers a broader consumer staples comparison for scale, brand investment and defensive demand.
Debt And Execution Risks Pressure KenvueKenvue ended the first quarter with total debt of about $8.7 billion, up from $8.5 billion at fiscal 2025-end. Interest expense was $95 million for the quarter, leaving less flexibility if operating trends weaken.
Execution risk also remains part of the investment case. Kenvue expects about $250 million of pre-tax restructuring expenses and other charges in 2026, continues to face product liability matters involving acetaminophen and talc-related products and is not providing 2026 financial guidance while the Kimberly-Clark transaction remains pending.
Kenvue Cash Flow Supports Investor AppealCash flow is a clearer positive. Operating cash flow rose to $489 million from $428 million in the prior-year period, mainly because of higher net income.
Capital expenditures declined to $139 million from $179 million, lifting free cash flow to roughly $350 million from about $249 million. Stronger cash generation can support dividends, debt management and continued investment behind core brands.
Kenvue’s Ranking Signals A Cautious Investment ProfileThe bottom line is that Kenvue’s margin progress and cash flow improvement make the stock more interesting, but the case is still balanced by slow organic growth, leverage and transaction-related uncertainty. The stock currently carries a Zacks Rank #3 (Hold), which fits a cautious profile rather than a clear near-term outperformer.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Style Scores also lean mixed. KVUE has a Value Score of C, Growth Score of C, Momentum Score of D and VGM Score of C. Since higher Style Scores are generally more favorable, these readings indicate limited broad-based strength across valuation, growth and momentum, even as operating execution has improved.
Odvolací soud v USA obnovil více než 500 žalob proti Kenvue kvůli údajnému spojení Tylenolu s autismem a ADHD. Akcie Kenvue v odpoledním obchodování klesly o 1,8 %.
A person poses with Tylenol in this illustration picture taken in Schwenksville, Pennsylvania, U.S. September 24, 2025. REUTERS/Hannah Beier Purchase Licensing Rights, opens new tab
SummaryCompaniesDecision restores more than 500 lawsuitsPanel says doctors used methodologies other scientists also useKenvue defends Tylenol, sees no scientific link to autism and ADHDShares of Kenvue fallNEW YORK, July 13 (Reuters) - A federal appeals court on Monday revived more than 500 private lawsuits against Tylenol maker Kenvue (KVUE.N), opens new tab over the painkiller's alleged link to autism.
The 2nd U.S. Circuit Court of Appeals in Manhattan said a district court judge improperly excluded expert testimony from three doctors offered by parents and guardians who tied Tylenol use during pregnancy to autism and attention deficit hyperactivity disorder (ADHD) in children.
The Reuters Daily Briefing newsletter provides all the news you need to start your day. Sign up here.
There is no firm scientific evidence of such a link. The issue drew greater attention after President Donald Trump and top U.S. health officials in September suggested a link to autism.
In a 64-page decision for a three-judge panel, Circuit Judge Guido Calabresi said the testimony from the three doctors, including the dean of Harvard University's School of Public Health, reflected methodologies used by other scientists, and "constitute acceptable interpretations of scientific evidence where scientists may, and in fact do, disagree."
Calabresi stressed that the appeals court was not deciding whether using acetaminophen causes autism or ADHD, or whether elected officials should do more to protect public health.
Doctors and medical societies consider acetaminophen, the active ingredient in Tylenol, the preferred means to treat pain and fever during pregnancy.
Many retailers and pharmacy operators including CVS (CVS.N), opens new tab, Kroger (KR.N), opens new tab, Target (TGT.N), opens new tab, Walgreens and Walmart (WMT.O), opens new tab were also named as defendants.
KENVUE DEFENDS TYLENOL'S SAFETYIn a statement on Monday, Kenvue maintained that Tylenol is safe, and said the decision "does not change the fact that credible, independent science shows no proven link between taking acetaminophen and autism or attention deficit hyperactivity disorder."
Kenvue plans to again try to show in court that the opinions of the plaintiffs' experts are unreliable.
In afternoon trading, Kenvue shares traded down 1.8% at $19.13, while Kimberly-Clark shares fell 2.7% to $109.34.
Johnson & Johnson (JNJ.N), opens new tab, Kenvue's former parent, made Tylenol for more than 60 years and has also defended its safety.
Kenvue agreed last November to be acquired by Kleenex tissue maker Kimberly-Clark (KMB.O), opens new tab for more than $40 billion. The transaction is expected to close this year. Kimberly-Clark did not immediately respond to requests for comment.
HARVARD DEAN'S TESTIMONY ALLOWEDThe appeals court said the doctors whose testimony was wrongly excluded included Harvard public health dean Andrea Baccarelli; Eric Hollander, a psychiatry professor at the Albert Einstein College of Medicine, and Brandon Pearson, a toxicologist at Columbia University.
"We are pleased that the panel unanimously found that our key experts reliably applied their scientific methods and principles," Ashley Keller, a lawyer for the parents, said in an email.
Experts often play a key role in product liability lawsuits such as the Tylenol cases.
Kenvue is based in Summit, New Jersey, and was spun off in 2023 by Johnson & Johnson.
The private lawsuits were dismissed in December 2024 by U.S. District Judge Denise Cote in Manhattan, who criticized the methodology of the plaintiffs' expert witnesses.
Monday's decision returns the lawsuits to Cote for further proceedings.
Reporting by Jonathan Stempel in New York; Additional reporting by Diana Novak Jones in Chicago; Editing by Chizu Nomiyama, Nick Zieminski, Nia Williams and David Gregorio
Our Standards: The Thomson Reuters Trust Principles., opens new tab
